Federal Practitioner

Supplement

Managing Advanced Hepatocellular Carcinoma

Rohit D. Divekar, MD, PhD and Paulette Mehta, MD, MPH, Hashem B. El-Serag, MD, MPH, Girindra G. Raval, MD, Emmanuel Tancinco, MD, Priyanka Raval, MBBS, Tamar Taddei, MD, Alexander Monto, MD, Jeffrey Kohlwes, MD, MPH

Fed Pract. 2009;26(suppl 1):1–24B.

This supplement to Federal Practitioner on hepatocellular carcinoma (HCC), supported by a grant from Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc., was developed with the aim of helping primary care providers in federal practice (especially those within the VA health care system) provide the highest quality care to their patients who are at risk for or have been diagnosed with HCC. It is our hope that, after reading this supplement, you will be better prepared to:

Identify patients at risk for HCC and initiate recommended screening and surveillance measures.
Recognize abnormal screening results, order appropriate diagnostic tests, and interpret the results of these tests.
Understand the strengths and weaknesses of the various HCC staging systems currently in use and apply them effectively.
Discuss the options available for treating HCC and their appropriate uses according to distinct patient and disease characteristics.
Know when to consult with specialists (such as gastroenterologists/hepatologists, radiologists, oncologists, and surgeons); when to refer patients to specialty care; and how to keep the lines of communication open between the multidisciplinary treatment team, the patient, and the family.
Provide early, effective, and ongoing patient education about all aspects of HCC to patients at risk and those who have been diagnosed with the disease.

[ PDF | Add to My Archive ]